证券代码：688247 证券简称：宣泰医药 公告编号：2025-013 上海宣泰医药科技股份有限公司 2024 年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会印发的《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号） 和上海证券交易所发布的《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关法律法规的规定及要求，上海宣泰医药科技股份有限公 司（以下简称"公司"或"宣泰医药"）董事会将公司 2024 年度募集资金存放与 实际使用情况专项说明如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1383 号），公司获准向社会公开发 行人民币普通股（A）股 45,340,000.00 股，发行价格为 9.37 元/股，募集资金总 额为人民币 4 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-016 上海宣泰医药科技股份有限公司 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1. 审议通过《关于公司 2024 年年度报告及摘要的议案》 监事会认为：公司 2024 年年度报告的编制和审议程序符合法律、法规、《公 司章程》和公司内部管理制度的各项规定；公司 2024 年年度报告的内容与格式 符合中国证券监督管理委员会和上海证券交易所的各项规定，所包含的信息能从 各方面客观、真实、公允地反映出公司当期经营管理和财务状况等事项；监事会 保证公司 2024 年年度报告所披露的信息真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《上海宣泰医药科技股份有限公司 2024 年年度报告摘要》、《上海宣泰医药科技 股份有限公司 202 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-015 上海宣泰医药科技股份有限公司 第二届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海宣泰医药科技股份有限公司（以下简称"公司"）第二届董事会第十五次 会议于 2025 年 4 月 28 日以现场方式召开。本次会议通知于 2025 年 4 月 18 日以 邮件形式发送。本次会议应出席董事 8 人，实际出席董事 8 人，会议由董事长叶 峻先生主持。会议的召集和召开程序符合《中华人民共和国公司法》等有关法律 法规及《公司章程》的规定。 二、董事会会议审议情况 1. 审议通过《关于公司 2024 年年度报告及摘要的议案》 董事会认为：公司 2024 年年度报告的编制和审议程序符合法律、法规、《公 司章程》和公司内部管理制度的各项规定；公司 2024 年年度报告的内容与格式 符合中国证券监督管理委员会和上海证券交易所的各项规定，所包含的信息能从 各方面客观、真实、公允地反映出公司当期经营管理和财务状况等事项 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-014 上海宣泰医药科技股份有限公司 关于 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配方案内容 （一）利润分配方案的具体内容 经上会会计师事务所（特殊普通合伙）审计确认，截至 2024 年 12 月 31 日， 公司 2024 年度实现归属于母公司股东的净利润为人民币 127,700,550.17 元，公 司 2024 年末母公司可供分配利润为人民币 231,866,342.70 元。经董事会审议， 公司 2024 年度拟以实施权益分派股权登记日登记的总股本扣减公司回购专用证 每股分配比例：每股派发现金红利 0.037 元（含税）。不进行资本公积金 转增股本，不送红股。 因上海宣泰医药科技股份有限公司（以下简称"公司"）实施股份回购 事项，根据相关规定，公司通过回购专用证券账户持有的本公司股份不 参与本次利润分配。本次利润分配以实施权益分派股权登记日的总股本 扣减公司回购专用证券账户中股份为基 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 108,926,965.45, a decrease of 2.23% compared to CNY 111,411,602.18 in the same period last year[4]. - Net profit attributable to shareholders was CNY 20,489,309.09, down 10.51% from CNY 22,895,905.48 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was CNY 19,067,636.31, reflecting a decrease of 12.33% compared to CNY 21,748,197.24 in the previous year[4]. - Total operating revenue for Q1 2025 was ¥108,926,965.45, a decrease of 2.2% compared to ¥111,411,602.18 in Q1 2024[18]. - Net profit for Q1 2025 was ¥20,489,309.09, down 10.5% from ¥22,895,905.48 in Q1 2024[19]. - Operating profit for Q1 2025 was ¥23,351,343.17, a decrease of 12.5% from ¥26,588,025.98 in Q1 2024[18]. - Total operating costs for Q1 2025 were ¥88,936,260.56, an increase of 3.5% from ¥85,556,447.58 in Q1 2024[18]. - Basic and diluted earnings per share for Q1 2025 remained at ¥0.05, unchanged from Q1 2024[19]. - Other comprehensive income after tax for Q1 2025 was -¥107.34, reflecting a decrease compared to the previous year[19]. Cash Flow and Investments - Operating cash flow for the period increased significantly by 127.92%, reaching CNY 65,588,203.74, compared to CNY 28,776,793.07 in the same period last year[4]. - Cash flow from operating activities for Q1 2025 was ¥65,588,203.74, significantly up from ¥28,776,793.07 in Q1 2024[23]. - Cash flow from investing activities for Q1 2025 was -¥142,392,271.43, an improvement from -¥409,037,270.16 in Q1 2024[24]. - Cash and cash equivalents decreased to RMB 148,955,862.02 from RMB 225,785,781.43, representing a decline of approximately 34.1%[13]. - Cash and cash equivalents at the end of Q1 2025 were ¥148,955,862.02, down from ¥229,422,987.49 at the end of Q1 2024[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,468,663,744.92, an increase of 1.06% from CNY 1,453,304,093.20 at the end of the previous year[5]. - As of March 31, 2025, the total assets of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. amounted to RMB 1,468,663,744.92, an increase from RMB 1,453,304,093.20 as of December 31, 2024, reflecting a growth of approximately 1.4%[13]. - The company's current assets totaled RMB 983,289,086.99, slightly up from RMB 976,317,889.19, indicating a growth of about 0.99%[13]. - The accounts receivable decreased significantly from RMB 103,524,626.45 to RMB 63,321,304.26, a reduction of about 38.9%[13]. - The total liabilities decreased from RMB 180,299,755.44 to RMB 175,170,098.07, a decline of approximately 2.4%[15]. - The company's equity attributable to shareholders increased from RMB 1,273,004,337.76 to RMB 1,293,493,646.85, reflecting a growth of about 1.6%[15]. - The inventory remained relatively stable, with a slight decrease from RMB 102,418,450.82 to RMB 102,397,398.38[14]. - The non-current assets totaled RMB 485,374,657.93, up from RMB 476,986,204.01, indicating an increase of approximately 1.6%[14]. Research and Development - R&D investment totaled CNY 12,449,732.66, a decrease of 19.44% from CNY 15,454,452.53 year-on-year, representing 11.43% of revenue, down from 13.87%[5]. - Research and development expenses for Q1 2025 were ¥12,449,732.66, a decrease of 19.5% compared to ¥15,454,452.53 in Q1 2024[18]. Shareholder Information - The company had a total of 8,389 preferred shareholders with restored voting rights at the end of the reporting period[8]. - The largest shareholder, Shanghai Lianhe Investment Co., Ltd., holds 51.40% of the shares, totaling 233,000,000 shares[10]. - The company has not reported any significant changes in major shareholders or their participation in financing activities during the reporting period[12]. Non-Recurring Gains and Losses - Non-recurring gains and losses for the period amounted to CNY 1,421,672.78, with government subsidies contributing CNY 506,833.79[6][7]. - The weighted average return on equity decreased to 1.60%, down 0.28 percentage points from 1.88% in the previous year[5].

Financial Performance - The company's operating revenue for 2024 reached ¥511,619,303.14, a year-on-year increase of 70.61% compared to ¥299,871,288.42 in 2023[23]. - Net profit attributable to shareholders was ¥127,700,550.17, reflecting a significant growth of 109.09% from ¥61,074,068.07 in the previous year[23][25]. - The net profit after deducting non-recurring gains and losses was ¥113,965,967.97, up 140.06% from ¥47,473,745.81 in 2023[23][25]. - Cash flow from operating activities surged to ¥130,230,119.87, a remarkable increase of 905.01% compared to ¥12,958,036.70 in the previous year[23][27]. - Basic earnings per share rose to ¥0.28, marking a 115.38% increase from ¥0.13 in 2023[24][27]. - The weighted average return on equity increased to 10.37%, up 5.23 percentage points from 5.14% in the previous year[24][27]. - The total cash dividend for the year amounts to 27.84 million CNY, which includes 11.23 million CNY distributed in the mid-year[6]. - The combined amount of cash dividends and share repurchases for the year is approximately 63.96 million CNY, representing 50.09% of the net profit attributable to shareholders[6]. Research and Development - Research and development expenses accounted for 16.60% of operating revenue, a decrease of 8.08 percentage points from 24.68% in 2023[24][27]. - The total R&D expenditure for the year was approximately ¥84.92 million, an increase of 14.75% compared to the previous year's ¥74.01 million, with R&D expenditure accounting for 16.60% of operating revenue, down from 24.68%[79]. - The company has 19 products under development, with 5 products approved for domestic and international markets during the reporting period[36]. - A total of 16 new domestic patents were applied for during the reporting period, including 10 invention patents[37]. - The company has established three core technology platforms, enhancing its R&D capability and creating high barriers to entry in the market[87]. - The company has maintained a strong focus on independent R&D since its establishment, ensuring a solid foundation for the continuous development of high-value products[68]. - The company has a strong R&D team, with over 40% of its researchers holding master's degrees or higher, ensuring robust technical capabilities[90]. Market Expansion and Sales - The company is actively expanding its international market presence, focusing on the U.S. and emerging markets along the "Belt and Road" initiative[35]. - The company achieved foreign sales revenue of 20,794.62 million yuan, accounting for 40.69% of its main business income, indicating its reliance on international markets[95]. - The company recorded equity income of CNY 46.82 million, which is a 122.30% increase compared to the previous year[35]. - The company’s international sales revenue surged by 120.64% year-on-year, mainly due to substantial sales growth of Mesalazine enteric-coated tablets and Bupropion sustained-release tablets in the U.S.[117]. - The company’s main products, including posaconazole enteric-coated tablets and mesalazine enteric-coated tablets, have significant market shares in the U.S. market and are included in the National Basic Medical Insurance Drug List[89]. Quality Management and Compliance - The company has established a comprehensive quality management system, conducting 1 internal audit and passing 12 external inspections during the reporting period, ensuring stable production operations[39]. - The company received a zero-defect rating from the FDA during a routine cGMP inspection in March 2024, affirming the effectiveness of its quality management system[40]. - The company has established long-term partnerships with major suppliers to ensure stable and reliable material supply, employing various procurement models to maintain quality and cost-effectiveness[45]. - The company has received multiple awards for its CRO/CMO services, including recognition as one of the "Top Ten Innovative Drug Service Institutions" by Securities Times[38]. Risks and Challenges - The company faces risks related to raw material price fluctuations, which could impact future performance if prices rise significantly[96]. - The company has a receivables balance of 10,352.46 million yuan, indicating potential risks associated with accounts receivable as business expands[99]. - The company’s inventory value stands at 10,241.85 million yuan, posing risks related to the timely realization of inventory as business grows[100]. - The company faced risks related to the national centralized procurement policy, which may affect the pricing and sales of its products, particularly posaconazole enteric-coated tablets[106]. - The company’s foreign sales are significantly impacted by international regulations and geopolitical factors, which pose potential risks to its export business[108]. Corporate Governance - The company has established a robust governance structure, holding 8 board meetings and reviewing 35 proposals during the reporting period[174]. - The board of directors consists of 8 members, all of whom are external directors, including 3 independent directors, complying with legal and regulatory requirements[175]. - The supervisory board held 5 meetings during the reporting period, reviewing 16 proposals, ensuring compliance with relevant laws and regulations[176]. - The company has maintained independence from its controlling shareholder, with no instances of fund occupation or guarantees provided to the controlling shareholder[178]. - The company issued 5 voluntary disclosure announcements throughout the year, including 3 product approval announcements and 1 project bidding announcement, enhancing market transparency[179]. Future Outlook - The company plans to deepen its focus on high-end generic drugs and expand into improved new drugs, enhancing its competitive edge[168]. - The company aims to increase R&D investment, particularly in complex injection formulations, to transition from a generic drug company to a hybrid innovative pharmaceutical enterprise[169]. - The company will enhance its CRO/CMO services, expanding its client base and deepening cooperation with existing clients[170]. - The company intends to expand its market presence both domestically and internationally, particularly in emerging markets and along the "Belt and Road" initiative[171].

上海宣泰医药科技股份有限公司 内部控制审计报告 上会师报字(2025)第 8050 号 上会会计师事务所（特殊普通合伙） 中国 ·计师 李 务所（转张善通合伙） Certified Public Accountants (Special General Partnership) 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情 况的变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根 据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 内部控制审计报告 上会师报字(2025)第 8050 号 上海宣泰医药科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们 审计了上海宣泰医药科技股份有限公司(以下简称"宣泰医药")2024年12月 31 日 的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评 价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是宣泰医药董事 会的责任。 二、注册会计师的责任 我们的责任是在实施审 ...

上会会计师事务所（特殊普通合伙） 中国 上海 the state of the state 令计师 李务所（特殊善通合伙） ahai Ecolidiad Public Slocoventants (Shocial Peneral Partnership) 关于上海宣泰医药科技股份有限公司 募集资金存放与使用情况的鉴证报告 上会师报字(2025)第 8051 号 关于上海宣泰医药科技股份有限公司 2024 年度募集资金存放与使用情况的鉴证报告 上会师报字(2025)第 8051 号 上海宣泰医药科技股份有限公司全体股东： 我们接受委托,对后附的上海宣泰医药科技股份有限公司(以下简称"宣泰医药") 《关于 2024 年度公司募集资金存放与实际使用情况的专项报告》执行了鉴证工作。 一、管理层对募集资金专项报告的责任 按照中国证监会发布的《上市公司监管指引第 2 号一上市公司募集资金管理和 使用的监管要求》和上海证券交易所发布的《上海证券交易所科创板上市公司自律 监管指引第 1 号 -- 规范运作》的规定编制《关于 2024年度公司募集资金存放与实 际使用情况的专项报告》是宣泰医药董事会的责任。这种责任包括设计、实施 ...

上会师报字(2025)第 8048 号 上海宣泰医药科技股份有限公司全体股东: 上海宣泰医药科技股份有限公司 审计报告 上会师报字(2025)第 8048 号 上会会计师事务所（特殊普通合伙） 中国 上海 ·计师事务所(特殊善通 lio Secountants (Sha 审计报告 一、审计意见 我们审计了上海宣泰医药科技股份有限公司（以下简称"宣泰医药"）财务报 表,包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司 利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及相关财务 报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公 允反映了宣泰医药 2024 年 12 月 31 目的合并及母公司财务状况以及 2024年度的合并 及母公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册 会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照 中国注册会计师职业道德守则,我们独立于宣泰医药,并履行了职业道德方面的其 他责任。我们相信,我们获取的审计证 ...

国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为上海 宣泰医药科技股份有限公司（以下简称"公司"或"宣泰医药"）的持续督导机 构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上 市公司募集资金管理和使用的监管要求》《上海证券交易所科创板股票上市规定》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规 定，对宣泰医药 2024 年度募集资金存放与使用情况进行了审慎核查，具体情况 如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 国泰海通证券股份有限公司 关于上海宣泰医药科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1383 号），公司获准向社会公开发 行人民币普通股（A）股 45,340,000.00 股，发行价格为 9.37 元/股，募集资金总 额为人民币 42,483.58 万元，扣除与发行相关的费用（不含增值税）人民币 4,761.77 万元，实际募集资金净额为人民币 37,721. ...